
Sreeven Pharma Private Limited
Pharmaceutical company manufacturing aceclofenac paracetamol tablets, antiseptic medicine, and bulk drugs.
Pharmaceutical company manufacturing aceclofenac paracetamol tablets, antiseptic medicine, and bulk drugs.
Sreeven Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 July 1992 and has a history of 32 years and seven months. Its registered office is in Rangareddy, Telangana, India.
The Corporate was formerly known as Richie Investments & Consultants Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.69 Cr.
The company currently has active open charges totaling ₹6.00 Cr. The company has closed loans amounting to ₹9.06 Cr, as per Ministry of Corporate Affairs (MCA) records.
Devendrappa Jegashetty and Sandeep Gokaraju serve as directors at the Company.
Rangareddy, Telangana, India
+91-XXXXXXXXXX
-
U65993TG1992PTC014481
014481
Private Limited Indian Non-Government Company
08 Jul 1992
22 Jul 2023
31 Mar 2023
Unlisted
Roc Hyderabad
Sreeven Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Anti Acne Drug, Brain & Nervous System Drugs, Immunomodulator Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Smoking Drugs, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Steroid.
Name | Designation | Appointment Date | Status |
---|---|---|---|
Devendrappa Jegashetty ![]() | Managing Director | 11-Apr-2003 | Current |
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sandeep Gokaraju ![]() | Director | 15-Jul-2022 | Current |
Sreeven Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 98.86% decrease. The company also saw a substantial fall in profitability, with a 20.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1143.23%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Sreeven Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Sandeep Gokaraju is a mutual person
Devendrappa Jegashetty is a mutual person
Sandeep Gokaraju is a mutual person
₹6.00 Cr
₹9.06 Cr
Date | Lender | Amount | Status |
---|---|---|---|
19 Aug 2024 | Axis Bank Limited | ₹6.00 Cr | Open |
27 Jan 2017 | Syndicate Bank | ₹1.20 Cr | Satisfied |
22 Feb 2016 | Canara Bank | ₹4.95 Cr | Satisfied |
26 Aug 2011 | Axis Bank Limited | ₹2.21 Cr | Satisfied |
31 Oct 2008 | Syndicate Bank | ₹7.00 M | Satisfied |
Unlock and access historical data on people associated with Sreeven Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Sreeven Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sreeven Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Axis Bank Limited amounted to Rs. 6.00 Cr with Charge ID 100972431 was registered on 19 Aug 2024.
Sreeven Pharma Private Limited last Annual general meeting of members was held on 22 Jul 2023 as per latest MCA records.
Sreeven Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Hyderabad.
A charge registered on 27 Jan 2017 via Charge ID 100083574 with Syndicate Bank was fully satisfied on 10 Oct 2022.
A charge registered on 22 Feb 2016 via Charge ID 10627736 with Canara Bank was fully satisfied on 10 Oct 2022.
Sandeep Gokaraju was appointed as a Director was appointed as a Director on 15 Jul 2022 & has been associated with this company since 2 years 7 months .
Sreeven Pharma Private Limited was incorporated on 08 Jul 1992.
The authorized share capital of Sreeven Pharma Private Limited is ₹ 5.00 Cr and paid-up capital is ₹ 3.69 Cr.
Currently 2 directors are associated with Sreeven Pharma Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Sreeven Pharma Private Limited is H.No. 11-15-25, Doctors Colony Lb Nagar India, Hyderabad, Telangana, 500074.
The corporate identification number (CIN) of Sreeven Pharma Private Limited is U65993TG1992PTC014481 and the company number is 014481 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Sreeven Pharma Private Limited has fallen by -98.86%.
The financial reports for the fiscal year 2023 indicates that The net worth of Sreeven Pharma Private Limited has experienced an downturn of -1143.23%.
As per the financial statements for fiscal Year 2023, The total open charges for Sreeven Pharma Private Limited amount to ₹ 6.00 Cr.
The most recent Balance Sheet for Sreeven Pharma Private Limited was filed with the ROC on 31 Mar 2023.
SP
PS
DP
JL
MJ